AIM: To perform a multidimensional analysis of the clinical study characteristics of endometriosis based on the ClinicalTrials.gov, providing comprehensive and objective information for researchers, clinicians, and clinical pharmacists. METHODS: A thorough investigation was conducted on clinical trials related to endometriosis, registered on the ClinicalTrials.gov from its inception to October 20, 2023. Relevant trial data were extracted and statistically analyzed using bibliometrics and comparative research methods. RESULTS: A total of 667 endometriosis clinical studies were registered globally, showing an annual increase. The United States (127 trials), France (70 trials), and Italy (57 trials) had the highest number of registered trials. Interventional studies were predominant (416 trials, 62.4%), followed by observational studies (251 trials, 37.6%). Within interventional studies, drug therapy was the primary intervention (223 trials, 53.6%). Despite endometriosis being a female condition, male subjects were also considered, with 6 trials specifically requiring male participants and 37 trials not restricting gender. Companies/corporations were the main funding sources, while public and governmental organizations provided relatively less funding. CONCLUSION: Clinical trial research on endometriosis is in a phase of growth, with drug therapy being the main treatment approach. However, there is a relative lack of investment and attention from public funds and governmental organizations.